Comparison of Efficacy and Safety between Octreotide and Somatostatin in the Treatment of Liver Cirrho-sis and Upper Digestive Tract Hemorrhage:a Meta-analysis
- VernacularTitle:奥曲肽与生长抑素治疗肝硬化上消化道出血疗效和安全性比较的Meta分析
- Author:
Jianrong ZHUANG
1
;
Peiying ZHENG
;
Huizhen GAN
Author Information
1. 解放军第180医院 药学科 福建泉州362000
- Keywords:
Octreotide;
Somatostatin;
Liver cirrhosis;
Upper digestive tract hemorrhage;
Meta-analysis
- From:
China Pharmacist
2017;20(12):2204-2208
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To compare the efficacy and safety of octreotide and somatostatin in the treatment of liver cirrhosis and up-per digestive tract hemorrhage. Methods:The randomized controlled trails ( RCTs) on the comparison between octreotide and soma-tostatin in the treatment of liver cirrhosis and upper digestive tract hemorrhage were searched from Cochrane Library, PubMed, Med-line, Embase, China National Knowledge Infrastructure(CNKI), VIP China Science and Technology Journal Database and Wanfang database (till February 2017). The randomized controlled trails meeting the inclusion criteria were collected and the quality of included RCTs was assessed according to the Cochrane Collaboration system review, and then Meta -analysis was performed using RevMan 5. 3 software after data extraction and bias risk assessment. Results:A total of 11 RCTs were included. Meta-analysis showed the efficacy of octreotide group was similar to that of somatostatin group (OR=1. 10, 95%CI:0. 79-1. 53, P=0. 56). The levels of blood transfu-sion and hemostasis of octreotide group were higher than those of somatostatin group (MD=0. 68, 95%CI:0. 54-0. 82, P<0. 01 and MD=6. 26, 95%CI:4. 89-7. 63, P<0. 01). The risk of abdominal pain in octreotide group was lower than that in somatostatin group (OR=0. 43, 95%CI:0. 22-0. 86, P=0. 02). The other adverse reactions were similar in both groups. Conclusion:The efficacy of octreotide is similar to that of somatostatin in the treatment of liver cirrhosis and upper digestive tract hemorrhage, and the effect of som-atostatin is quicker than that of octreotide with less blood transfusion. The adverse reactions are similar in both groups, except that oct-reotide has a lower risk of abdominal pain. The long-term safety of octreotide still needs to be confirmed by performing higher quality and large-sample RCTs.
